{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T01:24:30Z","timestamp":1783819470197,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ahjo.2023.100281","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:10:02Z","timestamp":1677244202000},"page":"100281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Sudden cardiac death prevention in the era of novel heart failure medications"],"prefix":"10.1016","volume":"27","author":[{"given":"I.","family":"Koev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yarkoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Luria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Biton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ahjo.2023.100281_bb0005","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2006.09.020","volume":"48","author":"Buxton","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.ahjo.2023.100281_bb0010","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/erc.11.103","article-title":"Myocardial fibrosis as a risk stratifier for sudden arrhythmic death","volume":"9","author":"Sovari","year":"2011","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"8","key":"10.1016\/j.ahjo.2023.100281_bb0015","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/CIRCULATIONAHA.104.529545","article-title":"The dynamics of cardiac fibrillation","volume":"112","author":"Weiss","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahjo.2023.100281_bb0020","doi-asserted-by":"crossref","first-page":"H1594","DOI":"10.1152\/ajpheart.00579.2009","article-title":"Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress","volume":"297","author":"Morita","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"10","key":"10.1016\/j.ahjo.2023.100281_bb0025","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jcmg.2019.10.021","article-title":"Sudden Cardiac Death in Ischemic Heart Disease: From Imaging Arrhythmogenic Substrate to Guiding Therapies","volume":"13","author":"Gr\u00e4ni","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"36","key":"10.1016\/j.ahjo.2023.100281_bb0030","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.ahjo.2023.100281_bb0035","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2015.9398","article-title":"Sacubitril\/Valsartan (Entresto) for heart failure","volume":"314","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ahjo.2023.100281_bb0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"15","key":"10.1016\/j.ahjo.2023.100281_bb0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ahjo.2023.100281_bb0050","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ahjo.2023.100281_bb0055","first-page":"e210","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"issue":"41","key":"10.1016\/j.ahjo.2023.100281_bb0060","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.ahjo.2023.100281_bb0065","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. antiarrhythmics vs implantable defibrillator study. cardiac arrest study Hamburg. Canadian implantable defibrillator study","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.ahjo.2023.100281_bb0070","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"Antiarrhythmics versus Implantable Defibrillators I. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias","volume":"337","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ahjo.2023.100281_bb0075","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the cardiac arrest study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahjo.2023.100281_bb0080","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/europace\/euq329","article-title":"Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis","volume":"12","author":"Theuns","year":"2010","journal-title":"Europace"},{"issue":"26","key":"10.1016\/j.ahjo.2023.100281_bb0085","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. multicenter automatic defibrillator implantation trial investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ahjo.2023.100281_bb0090","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ahjo.2023.100281_bb0095","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ahjo.2023.100281_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ahjo.2023.100281_bb0105","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ahjo.2023.100281_bb0110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator implantation early after myocardial infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ahjo.2023.100281_bb0115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable cardioverter-defibrillator after myocardial infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ahjo.2023.100281_bb0120","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.hrthm.2015.08.020","article-title":"Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: from the israeli ICD registry","volume":"12","author":"Sabbag","year":"2015","journal-title":"Heart Rhythm."},{"issue":"24","key":"10.1016\/j.ahjo.2023.100281_bb0125","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMoa1211107","article-title":"Reduction in inappropriate therapy and mortality through ICD programming","volume":"367","author":"Moss","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jacc.2007.08.058","article-title":"Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction","volume":"51","author":"Goldenberg","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100281_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000198","article-title":"A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?","volume":"2","author":"Ezzat","year":"2015","journal-title":"Open Heart"},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11536690-000000000-00000","article-title":"Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?","volume":"10","author":"Beri","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"7","key":"10.1016\/j.ahjo.2023.100281_bb0145","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0002-9149(97)00013-1","article-title":"Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure","volume":"79","author":"Dries","year":"1997","journal-title":"Am. J. Cardiol."},{"issue":"9 Suppl","key":"10.1016\/j.ahjo.2023.100281_bb0150","first-page":"S87","article-title":"Use of nonantiarrhythmic drugs for prevention of sudden cardiac death","volume":"14","author":"Alberte","year":"2003","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"14","key":"10.1016\/j.ahjo.2023.100281_bb0155","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4A","key":"10.1016\/j.ahjo.2023.100281_bb0160","doi-asserted-by":"crossref","first-page":"9I","DOI":"10.1016\/S0002-9149(98)00468-8","article-title":"Importance of beta blockade in the therapy of serious ventricular arrhythmias","volume":"82","author":"Reiter","year":"1998","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. a meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ahjo.2023.100281_bb0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.amjcard.2011.10.033","article-title":"How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with \"SCD-HeFT criteria?\"","volume":"109","author":"Zecchin","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ahjo.2023.100281_bb0175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100281_bb0180","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahjo.2023.100281_bb0185","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2023.100281_bb0190","article-title":"Association of Change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"1\u201311","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2023.100281_bb0195","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"1\u201310","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2023.100281_bb0200","article-title":"Angiotensin receptor-neprilysin inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction","volume":"1\u20133","author":"Drazner","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc. Ther."},{"issue":"10","key":"10.1016\/j.ahjo.2023.100281_bb0210","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin. Res. Cardiol."},{"issue":"10","key":"10.1016\/j.ahjo.2023.100281_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101582","article-title":"Impact of Sacubitril\/Valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients","volume":"8","author":"El-Battrawy","year":"2019","journal-title":"J. Clin. Med."},{"issue":"30","key":"10.1016\/j.ahjo.2023.100281_bb0220","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0225","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm."},{"issue":"10166","key":"10.1016\/j.ahjo.2023.100281_bb0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ahjo.2023.100281_bb0235","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0240","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular assessment study-renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"10254","key":"10.1016\/j.ahjo.2023.100281_bb0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ahjo.2023.100281_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-020-01042-3","article-title":"Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients","volume":"19","author":"Hwang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.ahjo.2023.100281_bb0260","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ibanez","year":"2021","journal-title":"JACC Heart Fail."},{"issue":"24","key":"10.1016\/j.ahjo.2023.100281_bb0265","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013149","article-title":"Associations between the cyclic guanosine monophosphate pathway and cardiovascular risk factors: MESA","volume":"8","author":"Ying","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100281_bb0270","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1152\/ajprenal.00197.2005","article-title":"Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition","volume":"290","author":"Wang","year":"2006","journal-title":"Am J Physiol Renal Physiol."},{"issue":"10","key":"10.1016\/j.ahjo.2023.100281_bb0275","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11886-021-01580-6","article-title":"Vericiguat for heart failure with reduced ejection fraction","volume":"23","author":"Lombardi","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"issue":"8","key":"10.1016\/j.ahjo.2023.100281_bb0280","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial","volume":"142","author":"Butler","year":"2020","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ahjo.2023.100281_bb0285","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1016\/j.ahjo.2023.100281_bb0295","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int. J. Cardiol."},{"issue":"9744","key":"10.1016\/j.ahjo.2023.100281_bb0300","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ahjo.2023.100281_bb0305","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12325-014-0147-3","article-title":"Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice","volume":"31","author":"Zugck","year":"2014","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0310","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.ahjo.2023.100281_bb0315","first-page":"475","article-title":"Dialysis therapy for volume overload: a feasible option to reduce heart failure hospitalizations in advanced heart failure","volume":"24","author":"Koev","year":"2022","journal-title":"Isr. Med. Assoc. J."},{"issue":"2","key":"10.1016\/j.ahjo.2023.100281_bb0320","first-page":"123","article-title":"The role of ivabradine and trimetazidine in the new ESC HF guidelines","volume":"2","author":"Milinkovic","year":"2016","journal-title":"Card. Fail. Rev."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0325","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1253\/circj.CJ-15-1112","article-title":"Heart rate control with if inhibitor, ivabradine, in japanese patients with chronic heart failure- a randomized, double-blind, placebo-controlled phase II study","volume":"80","author":"Tsutsui","year":"2016","journal-title":"Circ. J."},{"issue":"5","key":"10.1016\/j.ahjo.2023.100281_bb0330","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/ejhf.258","article-title":"Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT holter substudy","volume":"17","author":"Bohm","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"20","key":"10.1016\/j.ahjo.2023.100281_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204732","article-title":"Effect of ivabradine on cardiac ventricular arrhythmias: friend or foe?","volume":"10","author":"Okninska","year":"2021","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.ahjo.2023.100281_bb0340","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2023.100281_bb0345","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10741-020-09991-3","article-title":"Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?","volume":"27","author":"Vecchi","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"9851","key":"10.1016\/j.ahjo.2023.100281_bb0350","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0355","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0360","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/ehf2.13455","article-title":"Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study","volume":"8","author":"Jaffuel","year":"2021","journal-title":"ESC Heart Fail."},{"issue":"23","key":"10.1016\/j.ahjo.2023.100281_bb0365","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/eurheartj\/ehu522","article-title":"Sleep disordered breathing and post-discharge mortality in patients with acute heart failure","volume":"36","author":"Khayat","year":"2015","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ahjo.2023.100281_bb0370","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.109.901801","article-title":"Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study","volume":"122","author":"Gottlieb","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0375","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejheart.2006.08.003","article-title":"Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients","volume":"9","author":"Oldenburg","year":"2007","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0380","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.12270","article-title":"Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design","volume":"5","author":"Jaffuel","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10840-019-00623-x","article-title":"Heart failure as a substrate and trigger for ventricular tachycardia","volume":"56","author":"Alvarez","year":"2019","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"10.1016\/j.ahjo.2023.100281_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6032631","article-title":"LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model","volume":"2019","author":"Chang","year":"2019","journal-title":"Cardiovasc. Ther."},{"issue":"16","key":"10.1016\/j.ahjo.2023.100281_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168994","article-title":"Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias","volume":"22","author":"Sutanto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ahjo.2023.100281_bb0400","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"10.1016\/j.ahjo.2023.100281_bb0405","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100281_bb0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.ahjo.2023.100281_bb0415","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"issue":"14","key":"10.1016\/j.ahjo.2023.100281_bb0420","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1080\/14656566.2021.1937121","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options","volume":"22","author":"Hulot","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"issue":"15","key":"10.1016\/j.ahjo.2023.100281_bb0425","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week","volume":"76","author":"Emdin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ahjo.2023.100281_bb0430","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/2047487319854140","article-title":"Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the cardiac rehabilitation outcome study in heart failure (CROS-HF): a systematic review and meta-analysis","volume":"27","author":"Bjarnason-Wehrens","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9943","key":"10.1016\/j.ahjo.2023.100281_bb0435","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(14)61176-4","article-title":"Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial","volume":"384","author":"Hindricks","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ahjo.2023.100281_bb0440","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602223000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602223000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:31:59Z","timestamp":1763001119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602223000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":88,"alternative-id":["S2666602223000332"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2023.100281","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sudden cardiac death prevention in the era of novel heart failure medications","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2023.100281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100281"}}